Skip to main content

Table 3 Diagnostic accuracy of proteolytic enzymes, CEA and CA 19-9 in colorectal cancer.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

  CATB CATL uPA PAI-1 CEA CA 19-9
Cut-off (4.60) (1.12) (0.21) (18.90) (4.0) (37.0)
Sensitivity (%) 82 41 69 94 30 18
Specificity (%) 88 80 82 84 89 93
PPV (%) 82 58 72 79 65 62
PPV-Positive Prevalence (%) 43 19 33 40 26 23
NPV (%) 88 68 80 96 66 63
NPV-Negative Prevalence (%) 27 7 19 35 5 2
Accuracy (%) 86 65 77 88 66 63
Fisher's Exact Test P< 0.0001 P= 0.008 P< 0.0001 P< 0.0001 P= 0.004 P= 0.06
  1. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
  2. Abbreviations: PPV: Positive predictive value; NPV: Negative predictive value; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; Cut-off: cut-off values expressed in ng/ml; Positive Prevalence: the percentage of tumor patients in all patient groups investigated, i.e. 56/142 = 39%; Negative Prevalence: the percentage of non-tumor individuals in all patient groups investigated, i.e. 86/142 = 61%; PPV-Positive Prevalence: the difference between PPV and positive prevalence; NPV-Negative Prevalence: the difference between NPV and negative prevalence